Key Highlights

● MDT shares rose 1.84% to $87.97 on Monday, October 5, on 43.69 million shares, 2.31 times normal volume.

● Monday began the three-day pricing period for Medtronic's exchange offer for its remaining stake in MiniMed, which expires October 9.

● Medtronic shareholders can tender shares for MiniMed stock at a 7% discount, capped at 4.5939 MiniMed shares per Medtronic share.

● Fiscal first-quarter Revenue rose 13.7% to $9.76 billion, and management raised full-year organic revenue growth guidance to 7.25% to 7.75%.

What made Medtronic (NYSE:MDT) one of Monday's most heavily traded stocks was not a product launch or an Earnings surprise but the mechanics of a corporate breakup. Shares of the medical-device maker rose 1.84% to $87.97 on 43.69 million shares, 2.31 times normal volume, for about $3.84 billion in dollar volume, 20th among US stocks. Monday was the first day of the three-day pricing period for Medtronic's exchange offer to shed its remaining stake in diabetes Business MiniMed Group (NASDAQ:MMED), and that process gives arbitrage traders and long-term holders alike a reason to transact in the stock.

What's driving the volume

Medtronic took MiniMed public in March 2026 and kept roughly 90% of its shares, about 252.8 million. On September 14, it launched an exchange offer to complete the separation. Medtronic shareholders can tender their shares and receive MiniMed stock at a 7% discount to its market value. In practice, that means about $107.53 of MiniMed stock for every $100 of Medtronic stock tendered, subject to a cap of 4.5939 MiniMed shares per Medtronic share. Up to 225.4 million MiniMed shares are on offer, with room for about 27.5 million more if the offer is oversubscribed.

The exchange ratio is based on the average daily volume-weighted prices of both stocks over October 5, 6 and 7. The offer expires on October 9, and the final ratio is due to be announced the trading day before expiration. That timetable explains Monday's surge in activity. Event-driven investors commonly buy Medtronic shares to tender while selling MiniMed short, aiming to lock in the roughly 7.5% spread. Because the offer is widely expected to be oversubscribed, larger tenders face proration, but holdings of fewer than 100 Medtronic shares are accepted in full, which attracts many small arbitrage accounts. Other shareholders are deciding whether to keep Medtronic, swap into MiniMed or sell outright before the window closes.

There are risks in the trade. In mid-September the indicative ratio after the discount was already close to the 4.5939 cap, so a further drop in MiniMed would leave tendering holders short of the full 7% bonus. The offer would also put about 225 million shares into the hands of new holders, against a public float of only 28 to 29 million, raising the prospect of heavy selling pressure on MiniMed once the exchange settles.

Options traders were active, too: 24,238 Medtronic put contracts changed hands on Friday, about 45% above the typical daily volume. The backdrop for all of this is a stock that had been drifting lower: Medtronic closed at $86.38 on Friday and had lost about 5.4% over the prior 30 days and roughly 2.2% since the separation process began. Monday's gain, in a market where the S&P 500 rose 0.66%, therefore came on unusually heavy turnover rather than on any change in fundamentals.

The business

Medtronic is one of the world's largest medical-technology companies, with operations spanning cardiovascular devices, surgical tools, neuroscience products and, until the separation is complete, diabetes technology. Recent regulatory news has been steady. On October 1, the American Medical Association approved new Category I billing codes, effective in January 2028, for the Symplicity Spyral renal denervation system for uncontrolled hypertension and the Altaviva tibial neuromodulation device for urge incontinence. The company also won FDA clearance and a CE mark for its Affera Prism-2 cardiac mapping software, and its IN.PACT BTK balloon catheter received a Breakthrough Device designation.

Recent results and guidance

Medtronic's fiscal first-quarter results beat expectations. Revenue rose 13.7% to $9.76 billion, ahead of the roughly $9.55 billion consensus, although an extra week in the fiscal calendar added about $570 million, flattering the reported growth rate. Adjusted EPS was $1.45, above estimates of $1.39, and GAAP EPS rose 41% to $1.14. Cardiovascular sales were particularly strong. Management raised its full-year organic revenue growth forecast to 7.25% to 7.75%, from 6.75% to 7.25%, and guided to adjusted EPS of $5.94 to $6.00. For the fiscal second quarter it expects adjusted EPS of $1.32 to $1.34. Medtronic also pays a quarterly Dividend of $0.72 a share, a Yield of roughly 3.3%, payable on October 16.

Valuation

Medtronic's trailing P/E is 21.66, but on forward numbers the shares look cheaper. Based on the midpoint of fiscal 2027 adjusted EPS guidance, the stock trades at about 14.5 times earnings, compared with roughly 17 times for Abbott Laboratories (NYSE:ABT). Commentator Jim Cramer said on October 1 that he likes the company but questions what supports the multiple. Wall Street is more upbeat: the average price target is about $105 among 28 analysts, and TD Cowen maintained a $110 target. The stock remains well below its 52-week high of $106.33.

Bull case

Supporters argue that the MiniMed exit will leave a simpler, faster-growing company focused on cardiovascular, surgical and neuroscience markets, with better margins. Renal denervation and pulsed-field ablation are large opportunities, new billing codes improve the reimbursement path, guidance has just been raised, and a forward multiple in the mid-teens plus a 3% Dividend Yield offers a cushion.

Bear case

Skeptics note that headline growth was boosted by the extra week, that the stock has slipped since the separation began, and that a share count reduction from the exchange may not offset the loss of diabetes earnings. Arbitrage-driven trading can distort the price for several days, and any Reversal once the offer closes could weigh on the shares. Put buying suggests some investors are hedging that risk.

The exchange ratio, proration and a slimmer Medtronic

The immediate milestones are the end of the pricing period on October 7, the announcement of the final exchange ratio, and the offer's expiration on October 9, followed by proration results. If too few shares are tendered, Medtronic has said it intends to dispose of the remaining MiniMed stake through a spin-off, split-off or debt-for-equity exchange. After that, attention turns to fiscal second-quarter results, the adoption of renal denervation and how a slimmer Medtronic is valued without its diabetes unit.